B-intervention	0	10	Ultrasonic
I-intervention	11	21	dissection
I-intervention	22	28	system
I-intervention	29	39	technology
O	40	42	in
O	43	49	breast
O	50	56	cancer
O	56	57	:
O	58	59	a
O	60	64	case
O	64	65	-
O	65	72	control
O	73	78	study
O	79	81	in
O	82	83	a
O	84	89	large
O	90	96	cohort
O	97	99	of
O	100	108	patients
O	109	118	requiring
O	119	127	axillary
O	128	138	dissection
O	138	139	.

O	140	142	In
O	143	146	the
O	147	155	sentinel
O	156	160	node
O	161	164	era
O	164	165	,
O	166	174	axillary
O	175	185	dissection
O	186	187	(
O	187	191	ALND
O	191	192	)
O	193	196	for
O	197	203	breast
O	204	210	cancer
O	211	212	(
O	212	214	BC
O	214	215	)
O	216	218	is
O	219	227	required
O	228	232	much
O	233	237	less
O	238	248	frequently
O	249	253	than
O	254	256	in
O	257	260	the
O	261	265	past
O	265	266	.

O	267	274	However
O	274	275	,
O	276	289	complications
O	289	290	,
O	291	295	such
O	296	298	as
O	299	308	prolonged
O	309	317	drainage
O	318	324	output
O	325	328	and
O	329	335	seroma
O	336	345	formation
O	345	346	,
O	347	350	are
O	351	356	still
O	357	365	observed
O	365	366	.

O	367	375	Harmonic
O	376	386	dissection
O	387	394	devices
O	395	396	(
O	396	400	HDDs
O	400	401	)
O	402	405	are
O	406	412	widely
O	413	417	used
O	418	420	in
O	421	433	laparoscopic
O	434	437	and
O	438	447	minimally
O	448	456	invasive
O	457	464	surgery
O	465	467	to
O	468	474	reduce
O	475	485	collateral
O	486	492	damage
O	493	499	during
O	500	506	tissue
O	507	517	dissection
O	517	518	,
O	519	522	but
O	523	526	its
O	527	537	usefulness
O	538	540	in
O	541	547	breast
O	548	555	surgery
O	556	558	is
O	559	566	unclear
O	566	567	.

O	568	571	The
O	572	575	aim
O	576	578	of
O	579	583	this
O	584	589	study
O	590	593	was
O	594	596	to
O	597	605	evaluate
O	606	609	the
O	610	618	efficacy
O	619	621	of
O	622	626	HDDs
O	627	635	compared
O	636	638	to
O	639	643	that
O	644	646	of
O	647	659	conventional
O	660	670	dissection
O	671	673	in
O	674	684	performing
O	685	689	ALND
O	689	690	.

B-total-participants	691	694	One
I-total-participants	695	702	hundred
I-total-participants	703	709	thirty
I-total-participants	709	710	-
I-total-participants	710	714	nine
O	715	720	women
O	721	722	(
O	722	728	median
O	729	732	age
B-age	733	735	61
I-age	736	741	years
O	741	742	,
O	743	748	range
O	749	751	34
O	751	752	-
O	752	754	71
O	755	760	years
O	760	761	)
B-eligibility	762	766	with
I-eligibility	767	776	confirmed
I-eligibility	777	780	pT1
I-eligibility	780	781	-
I-eligibility	781	782	2
I-eligibility	783	790	primary
I-eligibility	791	803	infiltrating
I-eligibility	804	810	ductal
I-eligibility	811	813	BC
I-eligibility	814	824	undergoing
I-eligibility	825	833	curative
I-eligibility	834	841	surgery
O	842	846	were
O	847	855	enrolled
O	856	858	in
O	859	862	the
O	863	868	study
O	868	869	.

O	870	873	The
O	874	884	population
O	885	888	was
O	889	902	prospectively
O	903	913	randomized
O	914	921	between
O	922	925	two
O	926	929	age
O	929	930	-
O	931	934	and
O	935	940	stage
O	940	941	-
O	941	948	matched
O	949	953	arms
O	953	954	:
O	955	960	group
O	961	962	A
O	963	964	(
O	964	969	cases
O	969	970	)
O	970	971	-
B-intervention-participants	971	973	68
O	974	975	(
O	975	977	48
O	977	978	.
O	978	979	9
O	980	981	%
O	981	982	)
O	983	991	patients
O	992	993	(
O	993	996	HDD
O	997	1006	technique
O	1006	1007	)
O	1007	1008	,
O	1009	1015	versus
O	1016	1021	group
O	1022	1023	B
O	1024	1025	(
B-control	1025	1033	controls
O	1033	1034	)
O	1034	1035	-
B-control-participants	1035	1037	71
O	1038	1039	(
O	1039	1041	51
O	1041	1042	.
O	1042	1043	1
O	1044	1045	%
O	1045	1046	)
O	1047	1055	patients
O	1056	1057	(
O	1057	1069	conventional
O	1070	1079	technique
O	1079	1080	)
O	1080	1081	.

O	1082	1084	In
O	1085	1090	group
O	1091	1092	B
O	1092	1093	,
O	1094	1098	skin
O	1099	1104	flaps
O	1105	1109	were
O	1110	1118	obtained
O	1119	1124	using
O	1125	1126	a
O	1127	1134	scalpel
O	1134	1135	,
O	1136	1144	scissors
O	1144	1145	,
O	1146	1149	and
O	1150	1164	electrocautery
O	1165	1170	which
O	1171	1174	was
O	1175	1180	never
O	1181	1185	used
O	1186	1189	for
O	1190	1194	ALND
O	1194	1195	.

O	1196	1198	In
O	1199	1204	group
O	1205	1206	A
O	1206	1207	,
O	1208	1211	for
O	1212	1216	each
O	1217	1226	operation
O	1227	1231	time
O	1231	1232	,
O	1233	1236	the
O	1237	1241	HDDs
O	1242	1246	were
O	1247	1251	used
O	1252	1263	exclusively
O	1263	1264	.

O	1265	1268	The
B-outcome	1269	1273	mean
I-outcome	1274	1283	operative
I-outcome	1284	1288	time
O	1288	1289	,
B-outcome	1290	1304	intraoperative
I-outcome	1305	1310	blood
I-outcome	1311	1315	loss
O	1315	1316	,
O	1317	1320	and
B-outcome	1321	1329	drainage
I-outcome	1330	1336	output
O	1337	1341	were
O	1342	1343	(
O	1343	1344	A
O	1345	1347	vs
O	1347	1348	.
O	1349	1350	B
O	1350	1351	)
B-iv-cont-mean	1352	1354	95
O	1355	1356	±
B-iv-cont-sd	1357	1359	22
O	1360	1366	versus
B-cv-cont-mean	1367	1370	109
O	1371	1372	±
B-cv-cont-sd	1373	1375	25
I-cv-cont-sd	1376	1379	min
O	1379	1380	,
B-iv-cont-mean	1381	1383	56
O	1384	1385	±
B-iv-cont-sd	1386	1388	12
O	1389	1395	versus
B-cv-cont-mean	1396	1398	86
O	1399	1400	±
B-cv-cont-sd	1401	1403	15
I-cv-cont-sd	1404	1406	mL
O	1406	1407	,
O	1408	1411	and
B-iv-cont-mean	1412	1415	412
O	1416	1417	±
B-iv-cont-sd	1418	1420	83
O	1421	1427	versus
B-cv-cont-mean	1428	1431	456
O	1432	1433	±
B-cv-cont-sd	1434	1436	69
I-cv-cont-sd	1437	1439	mL
O	1439	1440	,
O	1441	1453	respectively
O	1454	1455	(
O	1455	1456	p
O	1457	1458	<
O	1459	1460	0
O	1460	1461	.
O	1461	1463	01
O	1463	1464	)
O	1464	1465	.

O	1466	1472	Twenty
O	1472	1473	-
O	1473	1477	nine
O	1478	1479	(
O	1479	1481	20
O	1481	1482	.
O	1482	1483	9
O	1484	1485	%
O	1485	1486	)
O	1487	1495	patients
B-outcome	1496	1505	developed
I-outcome	1506	1508	an
I-outcome	1509	1517	axillary
I-outcome	1518	1524	seroma
O	1524	1525	:
B-iv-bin-abs	1526	1527	9
O	1528	1529	(
B-iv-bin-abs	1529	1531	13
I-iv-bin-abs	1531	1532	.
I-iv-bin-abs	1532	1533	2
I-iv-bin-abs	1534	1535	%
O	1535	1536	)
O	1537	1540	and
B-cv-bin-abs	1541	1543	20
O	1544	1545	(
B-cv-bin-percent	1545	1547	28
I-cv-bin-percent	1547	1548	.
I-cv-bin-percent	1548	1549	2
I-cv-bin-percent	1550	1551	%
O	1551	1552	)
O	1553	1556	for
O	1557	1563	groups
O	1564	1565	A
O	1566	1569	and
O	1570	1571	B
O	1571	1572	,
O	1573	1585	respectively
O	1586	1587	(
O	1587	1588	p
O	1589	1590	=
O	1591	1592	0
O	1592	1593	.
O	1593	1596	030
O	1596	1597	)
O	1597	1598	.

O	1599	1602	Our
O	1603	1608	study
O	1609	1617	confirms
O	1618	1622	that
O	1623	1625	in
O	1626	1634	patients
O	1635	1639	with
O	1640	1642	BC
O	1643	1652	requiring
O	1653	1657	ALND
O	1658	1661	the
O	1662	1665	use
O	1666	1668	of
O	1669	1673	HDDs
O	1674	1676	is
O	1677	1681	more
O	1682	1686	time
O	1687	1696	efficient
O	1697	1701	than
O	1702	1714	conventional
O	1715	1722	surgery
O	1722	1723	,
O	1724	1727	and
O	1728	1735	reduces
O	1736	1750	intraoperative
O	1751	1759	bleeding
O	1759	1760	,
O	1761	1764	the
O	1765	1771	amount
O	1772	1774	of
O	1775	1783	drainage
O	1783	1784	,
O	1785	1788	and
O	1789	1792	the
O	1793	1797	risk
O	1798	1800	of
O	1801	1807	seroma
O	1808	1817	formation
O	1817	1818	.

O	1819	1824	These
O	1825	1832	results
O	1833	1836	may
O	1837	1841	lead
O	1842	1844	to
O	1845	1852	several
O	1853	1858	short
O	1858	1859	-
O	1860	1863	and
O	1864	1868	long
O	1868	1869	-
O	1869	1873	term
O	1874	1884	advantages
O	1884	1885	.

O	1886	1890	Thus
O	1890	1891	,
O	1892	1893	a
O	1894	1901	careful
O	1902	1912	evaluation
O	1913	1915	of
O	1916	1919	the
O	1920	1924	cost
O	1924	1925	-
O	1925	1933	benefits
O	1934	1936	of
O	1937	1951	nontraditional
O	1952	1957	tools
O	1957	1958	,
O	1959	1963	such
O	1964	1966	as
O	1967	1971	HDDs
O	1971	1972	,
O	1973	1979	should
O	1980	1982	be
O	1983	1992	performed
O	1993	1995	in
O	1996	1999	all
O	2000	2008	patients
O	2009	2019	undergoing
O	2020	2028	modified
O	2029	2036	radical
O	2037	2039	or
O	2040	2047	partial
O	2048	2058	mastectomy
O	2059	2062	and
O	2063	2067	ALND
O	2068	2071	for
O	2072	2074	BC
O	2074	2075	.
